Watson Pharmaceuticals last month partnered with Novartis Consumer Health to promote Watson's nicotine polacrilex gum, in 2 mg and 4 mg strengths.
Terms of the agreement were not disclosed.
"As a result [of this agreement], we are now able to make this product available to those over-the-counter customers we do not currently serve," stated Joe Papa, Watson's president and chief operating officer. Novartis currently markets OTC Habitrol nicotine replacement patches in the United States, as well as nicotine replacement gum under the brand name Nicotinell in the United Kingdom.
COPYRIGHT 2004 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group